Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Jasper Therapeutics launches with $35mm Series A round to develop HCT compound from Amgen; $14.1mm tranche added

Executive Summary

Jasper Therapeutics Inc. (hematopoietic cell transplants (HCTs) and gene therapies) launched with a $35mm Series A round co-led by Abingworth and Qiming Venture Partners. Surveyor Capital (an equities business of Citadel Capital) and Alexandria Venture Investments also participated.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies